

RPG LIFE SCIENCES LIMITED

Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030.

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2024

(Rs. in Lakhs)

Particulars	Quarter ended			Year ended	
	31-03-2024	31-12-2023	31-03-2023	31-03-2024	31-03-2023
	Audited	Unaudited	Audited	Audited	Audited
1 Revenue from Operations	12,699	15,370	11,849	58,205	51,281
2 Other Income	165	192	184	721	480
3 Total Income (1+2)	12,864	15,562	12,033	58,926	51,761
4 Expenses					
(a) Cost of Materials Consumed	2,803	2,485	2,242	12,065	8,612
(b) Purchases of Stock-in-Trade	1,492	1,649	2,026	6,118	9,205
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(151)	683	(319)	270	(730)
(d) Employee Benefits Expense	3,208	3,369	3,377	13,215	11,706
(e) Finance Costs	14	14	5	45	31
(f) Depreciation and Amortisation Expense	449	414	389	1,707	1,550
(g) Other Expenses	3,275	3,394	2,932	13,722	12,219
Total Expenses	11,090	12,008	10,652	47,142	42,593
5 Profit before tax (3-4)	1,774	3,554	1,381	11,784	9,168
6 Income tax expenses					
a. Current Tax	545	950	369	3,254	2,435
b. Deferred Tax	(95)	(42)	(23)	(236)	(31)
Total tax expenses	450	908	346	3,018	2,404
7 Profit for the period (5-6)	1,324	2,646	1,035	8,766	6,764
8 Other Comprehensive Income					
(i) Items that will not be reclassified to Profit or Loss	(82)	2	36	(75)	9
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	22	(1)	(9)	19	(2)
Other Comprehensive Income Net of Tax	(60)	1	27	(56)	7
9 Total Comprehensive Income for the period (7+8)	1,264	2,647	1,062	8,710	6,771
10 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323
11 Other Equity				36,162	29,437
12 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):					
(a) Basic (in Rs.)	8.01	16.00	6.26	53.01	40.90
(b) Diluted (in Rs.)	8.01	16.00	6.26	53.01	40.90

Audited Balance Sheet as at March 31, 2024

(Rs. in Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023
	(Audited)	(Audited)
ASSETS		
Non-current assets		
Property, plant and equipment (including Right of use assets)	9,703	10,127
Capital work-in-progress	8,478	1,503
Other intangible assets	1,650	2,299
Intangible assets under development	1,153	1,041
Financial assets		
i. Investments	101	
ii. Loans	19	18
iii. Other financial assets	43	44
Income Tax asset (Net)	122	173
Deferred tax assets (Net)	58	-
Other non-current assets	151	325
Total non-current assets	21,478	15,530
Current assets		
Inventories	10,100	9,505
Financial assets		
i. Investments	9,015	5,843
ii. Loans	-	2
iii. Trade receivables	4,913	3,743
iv. Cash and cash equivalents	1,972	2,482
v. Bank balances other than (iv) above	1,675	3,222
vi. Other financial assets	103	135
Other current assets	2,031	1,473
Total current assets	29,809	26,405
Total assets	51,287	41,935
EQUITY AND LIABILITIES		
Equity		
Equity share capital	1,323	1,323
Other equity	36,162	29,437
Total equity	37,485	30,760
LIABILITIES		
Non-current liabilities		
Financial liabilities		
i. Other financial liabilities	303	302
Provisions	403	398
Deferred tax liabilities (Net)	-	197
Total non-current liabilities	706	897
Current liabilities		
Financial liabilities		
i. Borrowings	-	1
ii. Trade payables		
(a) total outstanding dues of micro enterprises and small enterprises	503	482
(b) total outstanding dues of creditors other than micro enterprises and small enterprises	6,599	5,987
iii. Other financial liabilities	3,982	2,002
Provisions	1,217	1,186
Income tax liabilities (Net)	272	-
Other current liabilities	523	620
Total current liabilities	13,096	10,278
Total liabilities	13,802	11,175
Total equity and liabilities	51,287	41,935

Audited statement of cash flows for the year ended March 31, 2024

(Rs. in Lakhs)

	Particulars	For the period ended March 31, 2024	For the period ended March 31, 2023
		Audited	Audited
A	Cash Flow from operating activities		
	Profit before income tax	11,784	9,168
	Adjustments for		
	Add:		
	Depreciation and amortisation expenses	1,707	1,550
	Finance costs	45	31
	Profit on disposal of property, plant and equipment	(1)	78
	Unrealised exchange rate difference	(10)	46
	Provision for Doubtful Debts and Advances (Net)	270	50
	Less:		
	Interest received	(142)	(273)
	Provisions no longer required and written back	-	(7)
	Fair value gain arising on financial assets measured at fair value through profit and loss(net)	(472)	(144)
	Gain on sale of investments	(105)	-
		13,076	10,499
	Working capital adjustments:		
	(Increase) in trade receivables	(1,425)	(540)
	Decrease / (Increase) in financial assets - Loans	2	(8)
	Decrease in other financial assets	32	14
	(Increase) / Decrease in other current assets	(558)	443
	(Increase) in inventories	(595)	(1,206)
	Increase in trade payables	633	1,926
	Increase in other financial liabilities	1,338	539
	(Decrease) in provisions	(39)	(126)
	(Decrease) / Increase in other current liabilities	(97)	63
	Cash generated from operations	12,367	11,605
	Income taxes paid	(2,931)	(2,523)
	Net cash inflow from operating activities	9,436	9,082
B	Cash flow from investing activities:		
	Acquisition of property, plant and equipment and Intangible assets	(6,923)	(3,273)
	Proceeds from sale of property, plant and equipment and Intangible assets	15	8
	Movement in Other bank balances (Net)	1,547	(1,890)
	Investment in Mutual Funds	(4,350)	(5,699)
	Proceeds from sale of Mutual fund	1,755	-
	Investment in unquoted equity shares	(101)	-
	Interest received	142	273
	Net cash (outflow) from investing activities	(7,915)	(10,581)
C	Cash flow from financing activities		
	Proceeds from/ (Repayment of) long term borrowings	(1)	(1)
	Proceeds from/ (Repayment of) Short-term Borrowings	-	(27)
	Interest paid	(45)	(27)
	Repayment of principal portion of lease liability	-	(65)
	Interest paid on lease liability	-	(4)
	Dividend paid	(1,985)	(1,588)
	Net cash (outflow) from financing activities	(2,031)	(1,712)
	Net (decrease)/increase in cash and cash equivalents	(510)	(3,212)
	Add: Cash and cash equivalents at the beginning of the financial year	2,482	5,694
	Cash and cash equivalents at the end of the year	1,972	2,482

Notes:

1. The above results have been reviewed and recommended by the Audit Committee at its meeting held on April 29, 2024 and have been approved by the Board of Directors at its meeting held on April 30, 2024.
2. The Company operates in only one reportable business segment i.e. Pharmaceuticals.
3. Figures of the quarter ended March 31, 2024 and March 31, 2023 are the balancing figure between audited figures in respect of the full financial year and the year to date figures upto the third quarter of the relevant financial year which were subjected to limited review by Auditors.
4. The Board of Directors has recommended a final dividend of Rs.16 (Rupees 16 only) per equity share (200% on the face value of Rs 8 each) for the financial year 2023-24, subject to the approval of shareholders at the ensuing Annual General Meeting.

For RPG Life Sciences Limited

Yugal Sikri
Managing Director
Mumbai, April 30, 2024